Dr. med. Lorenz Bastian
Facts
Phone:
+49-431-500-22531
E-Mail:
lorenz.bastian@uksh.de
Website:
Affiliations:
Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
Address:
Arnold-Heller-Str. 3, Bldg L, 24105 Kiel
Curriculum vitae
Education/Training
| Since 2020 | Head of the Molecular Tumor Board, Campus Kiel University Cancer Center Schleswig-Holstein, Kiel, Germany |
| Since 2019 | Residency Internal Medicine and Hematology / Oncology, Clinic for Internal Medicine II, University Medical Center Schleswig-Holstein, Kiel, Germany |
| 2012-2018 | Residency Internal Medicine and Hematology / Oncology, Department of Medicine, Division of Hematology and Oncology, Charité – University Hospital Berlin, Germany |
| 2012 | Residency Internal Medicine, Department of Medicine, University Hospital Basel, Basel, Switzerland |
| 2009-2012 | Residency Pediatric Oncology and Hematology, Department of Pediatrics, Divison of Hematology and Oncology, Charité – University Hospital Berlin, Germany |
| 2008 | M. D. University Witten/Herdecke, Witten, Germany |
Research Experience/Academic Appointments
| Since 2019 | Senior Clinician Scientist, Research Group Functional Genomics of Acute Leukemias (AG Prof. Dr. med. Claudia Baldus), University Medical Center Schleswig-Holstein, Kiel, Germany |
| 2015-2018 | Clinician Scientist, Clinician Scientist Program, Berlin Institute of Health, Berlin, Germany, Research Group Translational Leukemia Research, Charité – University Hospital Berlin, Germany and Fellow, DKTK School of Oncology, German Cancer Consortium, Heidelberg, Germany |
| 2016-2018 | DKTK Investigator, German Cancer Consortium and German Cancer Research Center, Berlin and Heidelberg, Germany |
| 2008-2014 | Doctoral and Post-doctoral Researcher, Department of Pediatrics, Division of Hematology and Oncology, Charité – University Hospital Berlin, Germany |
Important Scientific Prizes/Functions
| 2019 | Poster prize, EMBO Workshop on “B cell development and leukemia”, Salamanca, Spain |
| 2017 | ASH Abstract Achievement Award, American Society of Hematology, Atlanta, USA |
| 2015 | ASH Abstract Achievement Award, American Society of Hematology, Orlando, USA |
Project-related publications
P1, P3, P4, P6, P7, Z
Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL
P1, P3, P4, P8, INF, Z
Isocitrate dehydrogenase 1 mutations drive downregulation of IL1R1 and dysregulated inflammatory response in acute myeloid leukemia
P1, P3, P4, INF
IntegrateALL: An end-to-end RNA-seq analysis pipeline for multilevel data extraction and interpretable subtype classification in B-precursor ALL
P1, P3, P4, INF
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response
P1, P3, P4, P6, INF, Z
Intra-subtype heterogeneity shapes treatment response in KMT2A-rearranged ALL across all age groups
P1, P3, P4, Z, INF, P6
IDH2 Clonal Hematopoiesis and IKAROS Loss Cooperate in a B-ALL Subtype after Lenalidomide Therapy for Multiple Myeloma
P1, P3, P4, Z
NGS-based IG/TR rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation
P1, P3, P4, INF
Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications
P1, P3, P4, INF, Z
The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age
P1, P3, P4, Z, INF
Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.
P1, P3, P4, INF, Z
IGH Rearrangement Evolution in Adult KMT2Arearranged B-cell Precursor ALL: Implications for Cell-of-origin and MRD Monitoring
P3, P4, P6, P7, Z
Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL
P1, P3, P4, INF, Z
UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment
P1, P4, P6
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
P1, P3, P4, Z